Aktive Positionen von Peter Trill
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Duke Street Bio Ltd.
 Duke Street Bio Ltd. BiotechnologyHealth Technology Duke Street Bio Ltd. is a British precision medicine company that targets specific genetic alterations in cancer using a DDR vulnerability approach. The company is based in London, UK. The company's goal is to deliver life-saving cancer treatments to improve patient outcomes. The company was founded in 2020. The CEO is Alan Wisee. | Vorsitzender | - | - |
| Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Peter Trill
Ehemalige bekannte Positionen von Peter Trill
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
IOmet Pharma Ltd.
 IOmet Pharma Ltd. Drugstore ChainsRetail Trade IOmet Pharma Ltd. develops drugs and related products. It focuses on developing the novel ideas sourced from universities, research institutes and industry as well as internally generated programs. The company was founded by Peter Trill and Tom Brown in 2010 and is headquartered in Scotland, the United Kingdom. | Finanzdirektor/CFO | 20.05.2010 | - |
| Gründer | 20.05.2010 | - |
Statistik
International
| Vereinigtes Königreich | 3 |
Operativ
| Director of Finance/CFO | 1 |
| Founder | 1 |
| Director/Board Member | 1 |
Sektoral
| Retail Trade | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
IOmet Pharma Ltd.
IOmet Pharma Ltd. Drugstore ChainsRetail Trade IOmet Pharma Ltd. develops drugs and related products. It focuses on developing the novel ideas sourced from universities, research institutes and industry as well as internally generated programs. The company was founded by Peter Trill and Tom Brown in 2010 and is headquartered in Scotland, the United Kingdom. | Retail Trade |
Duke Street Bio Ltd.
Duke Street Bio Ltd. BiotechnologyHealth Technology Duke Street Bio Ltd. is a British precision medicine company that targets specific genetic alterations in cancer using a DDR vulnerability approach. The company is based in London, UK. The company's goal is to deliver life-saving cancer treatments to improve patient outcomes. The company was founded in 2020. The CEO is Alan Wisee. | Health Technology |
- Börse
- Insiders
- Peter Trill
- Erfahrung
